Qingsong Health (HKEX: 02661) shares experienced a significant surge of over 20% in afternoon trading. At the time of writing, the stock was up 14.21% to HK$15.81, with a trading volume of HK$211 million.

Catalyst for the Move

The recent price movement follows the company's announcement that it has entered into a three-year strategic cooperation memorandum with Basel Medical Group Limited (Basel Medical, NASDAQ: BMGL).

The collaboration is centered around leveraging Qingsong Health's proprietary MedClaw healthcare AI collaboration system and AIcare technology stack, along with its extensive experience in implementing AI within the health sector. The primary goal is to foster mutual development through both technology export and iterative technological advancements.

Both parties believe that integrating the company's proven health AI infrastructure with Basel Medical's established clinical presence and market access in Southeast Asia will accelerate the region's transition towards intelligent healthcare services. This partnership is expected to unlock new market opportunities for both entities.

Furthermore, the companies plan to utilize the Qingsong Health AIcare technology stack as a foundation. This will support Basel Medical in upgrading its medical services with AI-native solutions across Southeast Asia and jointly expanding their regional market footprint, aiming to establish a durable and stable strategic partnership.